Metraipolis › archive › dc_ec038181cf43

[The use of tocilizumab in severe glucocorticoid-resistant endocrine ophthalmopathy with optic neuropathy in clinical practice] — Europe PMC PMID:41640161

Source
Europe PMC (rus)
Original
https://europepmc.org/article/MED/41640161
DOI
10.14341/probl13580
License (as archived)
solo-consultazione
Archived
2026-11-06T17:32:28.717Z
SHA-256 of the archived text
1a6b41d7970772e1c81d68ab6a55a22c674865ea5366a3c9ccbb444c69e221a8
Stable URL of this page
https://metraipolis.com/documento/dc_ec038181cf43

How to cite

[The use of tocilizumab in severe glucocorticoid-resistant endocrine ophthalmopathy with optic neuropathy in clinical practice] — Europe PMC PMID:41640161 — Europe PMC (rus), https://europepmc.org/article/MED/41640161 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ec038181cf43 (Metraipolis archive dc_ec038181cf43, sha256 1a6b41d7970772e1c81d68ab6a55a22c674865ea5366a3c9ccbb444c69e221a8)
BibTeX
@misc{dcec038181cf43,
  title = {[The use of tocilizumab in severe glucocorticoid-resistant endocrine ophthalmopathy with optic neuropathy in clinical practice] — Europe PMC PMID:41640161},
  howpublished = {Europe PMC (rus)},
  url = {https://europepmc.org/article/MED/41640161},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ec038181cf43; sha256 1a6b41d7970772e1c81d68ab6a55a22c674865ea5366a3c9ccbb444c69e221a8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41640161. Agents can read the archived copy with the MCP tool read_document.